PRESS RELEASE published on 07/01/2025 at 13:15, 5 months 4 days ago Bio Usawa becomes partner for the commercialization of FYB201/ BioUcenta™ (ranibizumab) across Sub-Saharan Africa Bio Usawa partners with Formycon AG for the commercialization of FYB201/BioUcenta™ (ranibizumab) in Sub-Saharan Africa, expanding access to ophthalmic treatment for diabetic complications Formycon AG Commercialization FYB201 Bio Usawa BioUcenta
BRIEF published on 06/27/2025 at 15:56, 5 months 7 days ago Formycon Successfully Places EUR 70 Million Bond Amid High Demand Biosimilars Investor Interest Capital Market EUR 70 Million Formycon Bond
BRIEF published on 06/27/2025 at 15:56, 5 months 7 days ago Formycon place avec succès une obligation de 70 millions d'euros dans un contexte de forte demande Marché Des Capitaux Biosimilaires Intérêt Des Investisseurs Liaison Formycon 70 Millions D'euros
PRESS RELEASE published on 06/27/2025 at 15:51, 5 months 7 days ago Formycon increases bond volume following oversubscription – Bond 2025/2029 with a volume of EUR 70 million successfully and entirely placed Formycon AG successfully and entirely places EUR 70 million bond 2025/2029 following oversubscription, interest rate fixed at 7.00% p.a Formycon AG Interest Rate Oversubscription EUR 70 Million Bond 2025/2029
BRIEF published on 06/27/2025 at 15:50, 5 months 8 days ago Formycon Secures EUR 70 Million Floating Rate Bond Formycon AG Financial Issuance Biosimilar Development EUR 70 Million Bond Floating Rate Bond
BRIEF published on 06/27/2025 at 15:50, 5 months 8 days ago Formycon obtient une obligation à taux variable de 70 millions d'euros Formycon AG Développement De Biosimilaires Émission Financière Obligation De 70 Millions D'euros Obligation À Taux Variable
PRESS RELEASE published on 06/27/2025 at 15:45, 5 months 8 days ago EQS-Adhoc: Formycon successfully places an EUR 70 million senior unsecured floating rate bond Formycon AG successfully places EUR 70 million senior unsecured floating rate bond, issued with a maturity of 4 years, financed for biosimilar product portfolio development Formycon AG Financial Market Senior Unsecured Bond Biosimilar Products EUR 70 Million
BRIEF published on 06/26/2025 at 06:35, 5 months 9 days ago Teva to Commercialize Formycon’s Biosimilar Fymskina® in Germany Germany Biosimilar Formycon Teva Fymskina®
BRIEF published on 06/26/2025 at 06:35, 5 months 9 days ago Teva commercialisera le biosimilaire Fymskina® de Formycon en Allemagne Allemagne Formycon Biosimilaire Teva Fymskina®
PRESS RELEASE published on 06/26/2025 at 06:30, 5 months 9 days ago Teva becomes secondary commercialization partner for Formycon's Stelara® biosimilar FYB202 (ustekinumab) under the brand name Fymskina® in Germany Teva partners with Formycon for commercialization of Stelara biosimilar FYB202 (ustekinumab) as Fymskina in Germany. Market launch planned in Q3 2025 Biosimilar Formycon Teva Stelara Fymskina
Published on 12/05/2025 at 15:35, 15 minutes ago XCF Global Moves to Double SAF Production with New Rise Reno Expansion
Published on 12/05/2025 at 15:00, 50 minutes ago Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Published on 12/05/2025 at 14:00, 1 hour 50 minutes ago Ocean Power Technologies Attending the 3rd Annual DealFlow Discovery Conference
Published on 12/05/2025 at 14:00, 1 hour 50 minutes ago Bonk, Inc. Highlights Major Ecosystem Milestone: Launch of Regulated BONK ETP on SIX Swiss Exchange
Published on 12/05/2025 at 15:39, 10 minutes ago Form 8.3 - The Vanguard Group, Inc.: Bakkavor Group plc
Published on 12/05/2025 at 15:38, 12 minutes ago Form 8.3 - The Vanguard Group, Inc.: Unite Group plc, The
Published on 12/05/2025 at 15:36, 13 minutes ago Form 8.3 - The Vanguard Group, Inc.: Dowlais Group plc
Published on 12/05/2025 at 15:35, 15 minutes ago Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Published on 12/05/2025 at 15:10, 39 minutes ago Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 15:10, 39 minutes ago Mersen : nombre d'actions et de droits de vote au 30 novembre 2025
Published on 12/05/2025 at 13:58, 1 hour 52 minutes ago RELATIF A LA MISE A DISPOSITION DU PUBLIC DE LA NOTE D'INFORMATION ET DES INFORMATIONS RELATIVES AUX CARACTERISTIQUES, NOTAMMENT JURIDIQUES, FINANCIERES ET COMPTABLES DE LEGRAND FRANCE
Published on 12/05/2025 at 08:45, 7 hours 5 minutes ago Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 7 hours 5 minutes ago Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry